Valneva reports final results from Phase II Lyme disease vaccine trial
Valneva has reported final safety and immunogenicity findings from the randomised Phase II trial, VLA15-221, assessing the Lyme disease vaccine…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Roche reports positive Phase III data of giredestrant for breast cancer
Roche has reported encouraging outcomes from its Phase III lidERA Breast Cancer trial of oral giredestrant as an adjuvant endocrine…
-
WCG unveils Data & Insights Solutions for clinical trials
WCG has introduced Data & Insights Solutions for optimising and expediting clinical study outcomes. The company aims to transform the…
-
Neurocrine’s depression treatment misses main goal in Phase II study
Neurocrine Biosciences has reported that its Phase II trial assessing NBI-1070770 in the adult population with major depressive disorder (MDD)…
-
EMA approves Arctic Therapeutics’ trial of AT-001 for Alzheimer’s
The European Medicines Agency (EMA) has granted approval to Iceland-based Arctic Therapeutics to commence a Phase IIa trial of small-molecule…
-
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint
Roche has reported that its Phase III ALLEGORY trial of Gazyva/Gazyvaro (obinutuzumab) in adult patients with systemic lupus erythematosus (SLE)…
-
ArkBio commences Phase II study of AK0610 for RSV prevention
Shanghai Ark Biopharmaceutical (ArkBio) has commenced a randomised Phase II study to evaluate the fully human monoclonal antibody, AK0610, for…
-
Thermo Fisher to buy Clario for $8.8bn
Thermo Fisher Scientific has reached a definitive agreement to acquire clinical trial endpoint data solutions provider Clario Holdings for $8.875bn…
-
Datavant and Indegene partner to improve trial subject recruitment
Data collaboration platform Datavant has partnered with life sciences commercialisation company Indegene to enhance recruitment of subjects for clinical studies.…
-
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study assessing the CD105 antagonist, ENV105 (carotuximab), in…